ERBB2 and gastric cancer: Therefore, nivolumab immunotherapy combined with chemotherapy has been recommended as the first-line therapy for HER2-negative advanced or metastatic GC with PD-L1 CPS ≥5 in the latest CSCO (2021 edition) guidelines.